Preventive Vaccines

Preventive Vaccines Market Outlook

The global preventive vaccines market is projected to reach approximately USD 50 billion by 2035, with a compound annual growth rate (CAGR) of around 6.5% during the forecast period from 2025 to 2035. The increasing prevalence of infectious diseases and the rising awareness about immunization programs are significant growth factors driving this market. Moreover, advancements in vaccine technology, such as the development of mRNA vaccines in response to the COVID-19 pandemic, have opened new opportunities for innovation in preventive vaccines. Additionally, government initiatives promoting vaccination and funding for research and development are further bolstering market growth. The ongoing efforts to expand vaccine accessibility globally, especially in low and middle-income countries, are expected to sustain the upward trajectory of this market.

Growth Factor of the Market

The preventive vaccines market is primarily driven by increasing incidences of infectious diseases globally, highlighting the need for effective vaccination programs. The rise in healthcare spending and government initiatives to promote vaccination, especially during outbreaks, also act as catalysts for market expansion. Technological advancements in vaccine development, such as the use of adjuvants to enhance immune response and the novel approaches of mRNA vaccine platforms, have revolutionized how vaccines are produced and administered. Furthermore, the growing public awareness of disease prevention and the efficacy of vaccines contribute positively to the demand for preventive solutions. The aging population, which is more susceptible to infectious diseases, coupled with the rising prevalence of chronic diseases, ensures a continuous need for vaccination across demographics.

Key Highlights of the Market

• Robust growth driven by rising incidences of infectious diseases.
• Technological innovations leading to advanced vaccine development.
• Government initiatives supporting vaccination awareness and accessibility.
• Increasing healthcare expenditure and investment in R&D for vaccines.
• Growing demand for vaccines in emerging markets due to increased healthcare access.

By Product Type

Inactivated Vaccines:

Inactivated vaccines are created from pathogens that have been killed or inactivated, rendering them incapable of causing disease. These vaccines stimulate an immune response without the risk of infection, making them suitable for various populations, including immunocompromised individuals. The growing demand for inactivated vaccines is attributed to their safety profile and efficacy against diseases such as influenza and hepatitis A. As public health initiatives emphasize vaccination, the inactivated vaccine segment is expected to witness substantial growth, particularly in regions facing outbreaks of vaccine-preventable diseases.

Live Attenuated Vaccines:

Live attenuated vaccines use a weakened form of the germ that causes a disease. This approach allows for a strong immune response, often resulting in long-lasting immunity. Common examples include the measles, mumps, and rubella (MMR) vaccine, as well as the oral polio vaccine. The effectiveness and longevity of the immunity provided by live attenuated vaccines contribute to their popularity, especially in pediatric vaccination programs. As vaccination schedules become increasingly optimized, the demand for live attenuated vaccines is expected to grow, driven by both public health policies and parental preferences for comprehensive immunization in children.

Subunit Vaccines:

Subunit vaccines consist of purified pieces of the pathogen, such as proteins or sugars, which help to provoke an immune response without using the live organism. This makes them a safer option with fewer side effects. Their effectiveness in inducing immunity against diseases like HPV and hepatitis B is well-documented. The market for subunit vaccines is anticipated to expand due to their favorable safety profile and the rising incidence of diseases that can be prevented through vaccination. Moreover, ongoing research and development in this area are leading to the introduction of new subunit vaccines, further propelling market growth.

Conjugate Vaccines:

Conjugate vaccines link antigens or toxoids from a pathogen to enhance the immune response. This type of vaccine is particularly effective for preventing diseases caused by encapsulated bacteria, such as pneumococcus and meningococcus. The success of conjugate vaccines in pediatric populations has led to their widespread adoption, particularly in immunization programs aimed at preventing infections in young children. As awareness of bacterial diseases increases and new conjugate vaccines are introduced, this segment is expected to see robust growth, particularly in developing regions where such infections are prevalent.

DNA Vaccines:

DNA vaccines utilize genetically engineered DNA to encode antigens, which stimulate an immune response. Although still largely in the experimental stages, they hold significant promise due to their ability to be rapidly developed and produced. The emergence of DNA vaccines has been accelerated by the need for fast response solutions, as seen during the COVID-19 pandemic. As research progresses and regulatory frameworks adapt, the DNA vaccine segment is likely to witness substantial growth, particularly in response to emerging infectious diseases and in veterinary applications.

By Application

Pediatric Vaccines:

Pediatric vaccines are crucial in preventing infectious diseases in children, as this demographic is particularly vulnerable to various pathogens. Vaccination programs for children have become an integral part of public health strategies worldwide, leading to a significant decline in diseases like measles, polio, and diphtheria. The growth of this segment is further supported by government recommendations and healthcare policies aimed at ensuring childhood immunization, which bolsters public awareness and parental compliance. As new vaccines are developed and added to immunization schedules, the pediatric vaccines segment is expected to expand consistently over the coming years.

Adult Vaccines:

The adult vaccination segment encompasses vaccines designed for individuals over the age of 18, addressing diseases such as influenza, hepatitis, and pneumococcal infections. With the global population aging and the prevalence of chronic diseases rising, the need for effective adult vaccination programs has become increasingly apparent. The segment is bolstered by initiatives promoting vaccination among adults, especially in high-risk groups. Increased awareness about the importance of preventive health measures and the efficacy of vaccines in reducing disease burden contribute to the growth of the adult vaccines market.

Travel Vaccines:

Travel vaccines are specifically designed to protect individuals against diseases prevalent in regions they plan to visit. With global travel increasing, the demand for travel-related immunizations has surged. Vaccines such as those for yellow fever, typhoid, and hepatitis A are essential for travelers, especially to areas where these diseases are endemic. The growing awareness of travel health and the establishment of vaccination requirements by various countries further enhance the demand for travel vaccines. As international travel continues to rebound post-pandemic, the travel vaccine segment is poised for significant growth.

Veterinary Vaccines:

Veterinary vaccines are vital for preventing diseases in animals, ensuring their health and productivity. This segment includes vaccines for pets, livestock, and wildlife, addressing diseases like rabies, canine distemper, and foot-and-mouth disease. The rise in pet ownership and awareness of animal health issues has driven the veterinary vaccine market's growth. As agricultural practices evolve and concerns regarding zoonotic diseases increase, the demand for veterinary vaccines is expected to rise sharply, particularly in regions where livestock is a significant economic activity.

Others:

This category includes various vaccines that do not fall into the previously mentioned segments. These can encompass niche markets for specific populations or diseases that are not widely recognized. The growth in this segment is driven by the ongoing research and development of new vaccines aimed at combating emerging infectious diseases and addressing specific public health concerns. As the scientific community continues to explore diverse vaccine formulations, the "others" segment is anticipated to grow as innovative solutions become available to target unmet healthcare needs.

By Distribution Channel

Hospitals:

Hospitals play a critical role in the distribution of vaccines, often serving as the primary point of care for immunizations. Many hospitals have integrated vaccination services into their outpatient departments, providing easy access for patients. The presence of trained healthcare professionals ensures that vaccinations are administered safely and effectively, thereby increasing public confidence in the immunization process. The hospital segment is expected to grow as healthcare systems emphasize preventive care and integrated health services, particularly in urban areas where hospitals are more accessible.

Clinics:

Clinics, including private practice and community health centers, are essential distribution channels for vaccines, offering flexibility and accessibility for patients seeking immunization. Many clinics provide specialized vaccination services, often catering to specific demographics, such as children or travelers. The convenience and personalized care offered by clinics enhance patient engagement and adherence to vaccination schedules. As vaccination rates continue to be a public health priority, the clinic segment is poised for growth, supported by initiatives to increase immunization coverage across various populations.

Retail Pharmacies:

Retail pharmacies have emerged as a significant player in the vaccine distribution landscape, offering convenient access to vaccinations without the need for appointment-based visits. Many pharmacies are equipped to administer vaccines, making it easier for individuals to receive their immunizations during routine shopping trips. The growth of this segment is driven by the increasing recognition of pharmacies as accessible healthcare providers and efforts to expand the range of services they offer. As more individuals seek convenience in healthcare access, the retail pharmacy segment is expected to continue growing robustly.

Online Pharmacies:

Online pharmacies are revolutionizing vaccine distribution by providing information and facilitating the procurement of vaccines. While the administration of vaccines still requires in-person visits, online pharmacies can play a role in educating patients about vaccination options and directing them to local providers. The rise in telehealth and digital healthcare solutions has further supported this trend, as patients seek convenient ways to manage their health. As the digital health landscape evolves, the online pharmacy segment is anticipated to gain traction, particularly among tech-savvy populations.

Others:

This category includes alternative distribution channels for vaccines, such as non-profit organizations, government vaccination programs, and outreach initiatives targeting underserved communities. These channels are vital for addressing healthcare disparities and ensuring that vaccines reach populations that may not have easy access to traditional healthcare settings. The growth of this segment is driven by increasing public health advocacy and the importance of equitable healthcare access. As global health initiatives continue to prioritize vaccination coverage, alternative distribution channels are expected to play an increasingly prominent role in the preventive vaccines market.

By Ingredient Type

Virus-based Vaccines:

Virus-based vaccines utilize attenuated or inactivated viruses to induce an immune response, effectively protecting against viral infections. Common examples include the measles, mumps, rubella (MMR) vaccine and the influenza vaccine. The effectiveness of virus-based vaccines in eliciting strong immune responses has led to their widespread use in vaccination programs worldwide. With ongoing research focusing on enhancing efficacy and safety, the virus-based vaccine segment is expected to grow significantly in response to increasing public awareness and the rising prevalence of viral infections.

Bacterial-based Vaccines:

Bacterial-based vaccines are designed to provide immunity against bacterial pathogens through the use of inactivated bacteria or their components. Vaccines such as those for tetanus and diphtheria fall into this category. The bacterial-based vaccine segment is driven by the need to prevent serious bacterial infections, particularly in vulnerable populations. As vaccination efforts expand globally and new bacterial vaccines are developed, this segment is expected to grow steadily, supported by public health initiatives aimed at addressing bacterial disease outbreaks.

Recombinant Vaccines:

Recombinant vaccines are produced using genetically engineered organisms to create antigens that stimulate immune responses. This innovative approach allows for the development of vaccines with enhanced safety and efficacy profiles. Notable examples include the HPV vaccine and certain hepatitis B vaccines. The recombinant vaccine segment is experiencing robust growth, fueled by advancements in biotechnology and increasing investment in vaccine research. As the demand for targeted and effective vaccination solutions rises, recombinant vaccines are likely to play a crucial role in the future of preventive healthcare.

Toxoid Vaccines:

Toxoid vaccines are designed to protect against toxins produced by certain bacteria rather than the bacteria themselves. By immunizing against these toxins, toxoid vaccines provide protection against diseases such as tetanus and diphtheria. The established efficacy of toxoid vaccines in preventing severe disease manifestations ensures their continued relevance in vaccination programs. As public awareness grows regarding the importance of preventing toxin-mediated diseases, the toxoid vaccine segment is expected to maintain steady growth, particularly in regions where such diseases remain endemic.

Others:

This category encompasses various innovative vaccine types that do not fit into the aforementioned classifications. It includes emerging technologies and novel formulations aimed at addressing specific health needs. The growth of this segment is driven by ongoing research and the need for personalized solutions in vaccination. As healthcare systems evolve and prioritize innovative preventive measures, the "others" segment is likely to expand, showcasing the dynamic nature of vaccine development and the continuous search for effective solutions to combat infectious diseases.

By Region

The North American region is currently the largest market for preventive vaccines, accounting for over 40% of the global market share. This dominance can be attributed to the well-established healthcare infrastructure, high levels of vaccination awareness, and significant investment in research and development for vaccine innovation. The region is also home to several leading vaccine manufacturers and research institutions, leading to rapid advancements in vaccine technology. Moreover, government initiatives and public health policies in North America strongly promote vaccination, further solidifying the region's leading position in the preventive vaccines market. The CAGR for this region is projected at about 5.5% during the forecast period, driven by a focus on preventive healthcare.

In Europe, the preventive vaccines market is characterized by stringent regulatory frameworks and advanced healthcare systems that foster vaccine innovation and distribution. The region is witnessing a steady increase in vaccination coverage rates, particularly in Eastern Europe, where initiatives are being implemented to enhance immunization access. The European market is anticipated to grow at a CAGR of approximately 6% between 2025 and 2035, driven by public health campaigns aimed at increasing awareness and uptake of vaccines. In the Asia Pacific region, rapid urbanization, growing healthcare expenditure, and increasing disease outbreaks are contributing to significant growth in the preventive vaccines market. As countries in this region prioritize healthcare accessibility, the market is expected to expand at a CAGR of around 7.5% during the forecast period.

Opportunities

The opportunities in the preventive vaccines market are vast, primarily due to the ongoing advancements in vaccine technology and research. The adoption of novel vaccine platforms, such as mRNA technologies, offers significant potential for rapid response to emerging infectious diseases. With the lessons learned from the COVID-19 pandemic, there is a heightened focus on the need for vaccines to be developed swiftly and effectively. This paradigm shift can lead to increased investments in vaccine research and development, fostering further innovation. Moreover, expanding vaccine accessibility in developing regions presents a unique opportunity for manufacturers to tap into underserved markets. With government support and initiatives aimed at improving healthcare infrastructure, the demand for preventive vaccines in these areas is expected to grow substantially, providing a lucrative opportunity for stakeholders.

Another promising opportunity lies in the development of combination vaccines that provide immunity against multiple diseases with a single shot. This approach not only improves vaccination compliance but also enhances the cost-effectiveness of immunization programs. Additionally, as public health awareness increases, there is a growing demand for personalized vaccines tailored to individual health needs, particularly in the context of chronic disease prevention. Manufacturers that invest in research and collaboration with public health organizations can gain a competitive edge in delivering innovative vaccines that cater to specific demographic requirements. The increasing prevalence of zoonotic diseases also opens avenues for veterinary vaccines, making it a potent area for investment and growth, especially as the interconnectivity between human and animal health becomes more recognized.

Threats

Despite the promising growth prospects in the preventive vaccines market, there are notable threats that could hinder progress. One significant challenge is the rising vaccine hesitancy among certain populations, driven by misinformation and distrust in vaccine safety. This apprehension can lead to lower vaccination rates, resulting in potential outbreaks of preventable diseases. Social media and online platforms often propagate misinformation, complicating public health messaging efforts. As vaccine preventable diseases could resurge in populations with low vaccination coverage, addressing this threat requires concerted efforts from both healthcare providers and policymakers to enhance public trust and education regarding vaccines. Furthermore, geopolitical issues and trade restrictions could disrupt vaccine supply chains, impacting availability and affordability, especially in developing regions.

Another critical threat to the preventive vaccines market is the emergence of new infectious diseases and vaccine-resistant strains of pathogens. As seen with the rapid evolution of viruses like SARS-CoV-2, the landscape of infectious diseases can change dramatically, posing challenges in vaccine efficacy and development timelines. Additionally, the regulatory environment for vaccine approval is becoming more stringent, which may slow down the introduction of new vaccines to the market. Companies must navigate complex regulatory pathways that can delay the availability of innovative solutions. In summary, while there are promising opportunities for growth in the preventive vaccines market, the challenges posed by vaccine hesitancy, emerging diseases, and regulatory hurdles must be addressed to ensure sustained progress.

Competitor Outlook

• Pfizer Inc.
• Moderna, Inc.
• GlaxoSmithKline plc
• Sanofi S.A.
• Merck & Co., Inc.
• Johnson & Johnson
• AbbVie Inc.
• Novartis International AG
• Roche Holding AG
• AstraZeneca plc
• Bharat Biotech
• Serum Institute of India
• Emergent BioSolutions Inc.
• VBI Vaccines Inc.
• Inovio Pharmaceuticals, Inc.

The competitive landscape of the preventive vaccines market is characterized by a diverse array of companies ranging from established pharmaceutical giants to innovative biotech firms. Major players like Pfizer, Moderna, and GlaxoSmithKline are at the forefront of vaccine development and distribution, leveraging their expertise and extensive resources to bring new vaccines to market swiftly. These companies are heavily investing in research and development, particularly in response to the growing demand for novel vaccines prompted by the COVID-19 pandemic. The focus on mRNA technology has revolutionized vaccine development, and companies that can harness this technology effectively have a competitive advantage in the market.

Emerging biotech firms are also making significant strides in the preventive vaccines market, often specializing in specific niches or innovative vaccine modalities. Companies like Inovio Pharmaceuticals and VBI Vaccines are exploring cutting-edge vaccine technologies, including DNA and recombinant vaccines, which present unique approaches to combating infectious diseases. As public health threats evolve, these firms are nimble and adaptive, allowing them to respond to emerging health challenges swiftly. The collaborative nature of the industry is evident, with many firms entering partnerships or alliances with research institutions and governments to accelerate vaccine development and expand their market reach.

In addition, regional players such as Bharat Biotech and the Serum Institute of India are gaining prominence, particularly in emerging markets. These companies are focusing on developing cost-effective vaccines that cater to regional health needs, often collaborating with global organizations to enhance vaccine accessibility. The competitive landscape is shaped by not only the scale of production and distribution capabilities but also by the ability to innovate and respond to public health priorities. As the demand for preventive vaccines continues to grow, the players that can balance innovation with accessibility will likely lead the market in the coming years.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 AbbVie Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Pfizer Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Sanofi S.A.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Moderna, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Bharat Biotech
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AstraZeneca plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 VBI Vaccines Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GlaxoSmithKline plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Serum Institute of India
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Novartis International AG
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Emergent BioSolutions Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Inovio Pharmaceuticals, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Preventive Vaccines Market, By Application
    • 6.1.1 Pediatric Vaccines
    • 6.1.2 Adult Vaccines
    • 6.1.3 Travel Vaccines
    • 6.1.4 Veterinary Vaccines
    • 6.1.5 Others
  • 6.2 Preventive Vaccines Market, By Product Type
    • 6.2.1 Inactivated Vaccines
    • 6.2.2 Live Attenuated Vaccines
    • 6.2.3 Subunit Vaccines
    • 6.2.4 Conjugate Vaccines
    • 6.2.5 DNA Vaccines
  • 6.3 Preventive Vaccines Market, By Ingredient Type
    • 6.3.1 Virus-based Vaccines
    • 6.3.2 Bacterial-based Vaccines
    • 6.3.3 Recombinant Vaccines
    • 6.3.4 Toxoid Vaccines
    • 6.3.5 Others
  • 6.4 Preventive Vaccines Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Clinics
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Online Pharmacies
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Preventive Vaccines Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Preventive Vaccines market is categorized based on

By Product Type

• Inactivated Vaccines
• Live Attenuated Vaccines
• Subunit Vaccines
• Conjugate Vaccines
• DNA Vaccines

By Application

• Pediatric Vaccines
• Adult Vaccines
• Travel Vaccines
• Veterinary Vaccines
• Others

By Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies
• Others

By Ingredient Type

• Virus-based Vaccines
• Bacterial-based Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Moderna, Inc.
• GlaxoSmithKline plc
• Sanofi S.A.
• Merck & Co., Inc.
• Johnson & Johnson
• AbbVie Inc.
• Novartis International AG
• Roche Holding AG
• AstraZeneca plc
• Bharat Biotech
• Serum Institute of India
• Emergent BioSolutions Inc.
• VBI Vaccines Inc.
• Inovio Pharmaceuticals, Inc.